Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.
September 8, 2006
Standard Dosage Works for Overweight
by Tim Horn
Size doesn’t matter. This is the conclusion of a new
study exploring whether people with high body mass indexes (BMI) –
those who are overweight or obese – are less likely to respond
favorably to HIV treatment. The data, published in the September issue
of the Journal of Acquired Immune Deficiency Syndromes, refutes
the hypothesis that larger-than-average HIV-positive people may need to
be treated with higher doses of HIV medications to achieve durable viral load suppression and stable CD4 cell counts.
Studies
have demonstrated that BMI can influence the way drugs are metabolized
and distributed in the body. For example, a possible reason why women
may be more likely to experience certain side effects – or have more severe side effect symptoms – is
because their average body weights are lower than the average body
weights of the males that make up the vast majority of dose-determining
clinical trials. In other words, some women may be taking higher doses
of a drug than they need, based on their lower body weight.
On
the other end of the spectrum are people who are overweight or obese.
The U.S. Centers for Disease Control’s HIV Outpatient Study (HOPS)
conducted a study to evaluate whether overweight or obese HIV-positive
people – who, like people of lower-than-average body weight may not be adequately represented in clinical trials – are more likely to experience treatment failure, due to the possibility of too little medication in their bodies.
Using
data collected in HOPS, an ongoing cohort involving thousands of
HIV-positive people, Ellen Tedaldi, MD, and her colleagues analyzed the
association of BMI with achieving an undetectable viral load and
experiencing a CD4 count increase of more than 100 cells after three to
nine month of HIV treatment.
Among 711 patients included
in analysis, 43% had a BMI of more than 25, which is considered to be
overweight or obese.* Higher BMI was associated with being female,
being black or Hispanic, being heterosexual, and using injection drugs.
Although average pre-treatment viral loads were significantly lower in
obese participants, overweight or obese BMI did not significantly alter
the likelihood of achieving an undetectable viral load and a CD4 cell
count increase of more than 100 cells compared with lower-weight study
participants.
In conclusion, Dr. Tedali’s group
indicated that a substantial proportion of the patients included in the
HOPS analysis were overweight or obese. However, increased BMI was not
associated with decreased virologic or immunologic responses to HIV
treatment. This, they suggest, argues against the likelihood of
requiring higher-dose treatment to manage HIV in larger-than-average
patients.
Other studies, exploring the possibility of
using lower-dose therapy in HIV-positive people with below-average body
weights to potentially reduce the risk of side effects, have not yet
been conducted.
* To calculate your BMI,
first multiply your height in inches by your height in inches (e.g., 74” X
74” = 5,476). Next divide that number into your body weight (e.g., 200
/ 5476 = 0.0365). Finally multiple that number by 703 (0.0365 X 703 =
25.66). This final number is your BMI. The National Heart, Lung, and
Blood Institute has an automated calculator that can be used to calculate your BMI.
While
BMI is considered to be a reliable indicator of total body fat, it does
have some limits. It may overestimate body fat in people who have
muscular builds and may underestimate body fat in some people,
including people with AIDS-related wasting, who have lost muscle mass.